The presentation of new data for a cancer vaccine candidate at a significant conference like AACR 2024 is likely to generate positive sentiment among investors and analysts, potentially leading to an increase in stock value. Given the direct involvement of IO Biotech's product, this news is highly relevant and important for investors in IOBT. The confidence in this analysis is based on historical trends where biotech firms presenting promising data at major conferences often see short-term stock price increases.